NCIA has been leading a coalition of scientists, doctors, CBD and Hemp entrepreneurs, and FDA lawyers to inform and influence FDA rule-making on CBD. Public comments were submitted to the FDA before the July 2, 2019 deadline. NCIA's Director of Public Policy, Andrew Kline, testified at FDA's public hearing on May 31, 2019. The panelists in this session lead the drafting and editing of our coalition's public comments and will discuss the questions asked by the FDA, the answers provided by our coalition and anticipated regulatory actions by the FDA.

Learning Objectives:
1. Learn about what the FDA was interested in learning about and why.
2. Gain a better understanding of how our industry coalition responded to the FDA's scientific questions.
3. Learn about the panel's predictions for how the FDA will regulate CBD/Hemp and what this might mean for cannabis.